28. (AMENDED) A method of treating and/or preventing a condition in need of a therapeutic regimen comprising a steroid, an antifungal agent, an antibacterial agent, or an anticancer agent, the method comprising the step of administering a self-emulsifying system comprising a mixture of a therapeutically effective amount of at least one extremely water-insoluble, lipophilic active agent; polyvinylpyrrolidone; a fatty acid; and a surfactant to an individual in need thereof, wherein the weight ratio of said fatty acid to said polyvinylpyrrolidone is about 2:1 to about 1:3.

A2

29. (AMENDED) The method of claim 28, wherein the weight ratio of said surfactant to said polyvinylpyrrolidone is about 10:1 to about 1:1.

35. (AMENDED) Use of a composition comprising ~~an extremely water-~~ insoluble, lipophilic active agent, polyvinylpyrrolidone, a fatty acid, and a surfactant, wherein the weight ratio of said fatty acid to said polyvinylpyrrolidone is about 2:1 to about 1:3, for the manufacture of a medicament for a condition in need of a therapeutic regimen comprising an active agent selected from the group consisting of a steroid, an antifungal agent, an antibacterial agent, and an anticancer agent.

A3

REMARKS

Support for the foregoing amendments of claims 1, 2, 28, 29, and 35 can be found in the application as originally filed at page 17, line 32 to page 18, line 1, claims 2 and 29, and elsewhere throughout the specification.

The applicant respectfully submits that all claims are now of proper form and scope for allowance. Early and favorable consideration is respectfully requested.

Attached hereto is a marked-up version of the changes made to the claims by the foregoing amendments. The attached page is captioned "**Version with markings to show changes made.**"

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN

By: _____

James P. Zeller
Reg. No. 28,491
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606-6402
(312) 474-6300

August 13, 2002

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS:

AMEND Claims 1, 2, 28, 29 and 35 as follows:

1. (AMENDED) A self-emulsifying drug delivery system comprising a mixture of an extremely water-insoluble, lipophilic active agent; polyvinylpyrrolidone; a fatty acid; and a surfactant, wherein the weight ratio of said fatty acid to said polyvinylpyrrolidone is about 2:1 to about 1:3.

2. (AMENDED) The self-emulsifying drug delivery system of claim 1, wherein [the weight ratio of said fatty acid to said polyvinylpyrrolidone is about 2:1 to about 1:3, and]the weight ratio of said surfactant to said polyvinylpyrrolidone is about 10:1 to about 1:1.

28. (AMENDED) A method of treating and/or preventing a condition in need of a therapeutic regimen comprising a steroid, an antifungal agent, an antibacterial agent, or an anticancer agent, the method comprising the step of administering a self-emulsifying system comprising a mixture of a therapeutically effective amount of at least one extremely water-insoluble, lipophilic active agent; polyvinylpyrrolidone; a fatty acid; and a surfactant to an individual in need thereof, wherein the weight ratio of said fatty acid to said polyvinylpyrrolidone is about 2:1 to about 1:3.

29. (AMENDED) The method of claim 28, wherein [the weight ratio of said fatty acid to said polyvinylpyrrolidone is about 2:1 to about 1:3 and]the weight ratio of said surfactant to said polyvinylpyrrolidone is about 10:1 to about 1:1.

35. (AMENDED) Use of a composition comprising an extremely water-insoluble, lipophilic active agent, polyvinylpyrrolidone, a fatty acid, and a surfactant, wherein the

weight ratio of said fatty acid to said polyvinylpyrrolidone is about 2:1 to about 1:3, for the manufacture of a medicament for a condition in need of a therapeutic regimen comprising an active agent selected from the group consisting of a steroid, an antifungal agent, an antibacterial agent, and an anticancer agent.